Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Hold" by Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) has earned an average rating of "Hold" from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $10.14.

Several analysts recently issued reports on the stock. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $4.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. HC Wainwright dropped their price target on Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. William Blair cut Neumora Therapeutics from an "outperform" rating to a "market perform" rating in a report on Monday, March 10th. Guggenheim lowered Neumora Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, March 7th. Finally, Stifel Nicolaus downgraded Neumora Therapeutics from a "buy" rating to a "hold" rating and cut their target price for the stock from $6.00 to $2.00 in a research note on Friday, March 7th.

Institutional Trading of Neumora Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Intech Investment Management LLC purchased a new position in Neumora Therapeutics during the third quarter worth about $175,000. Charles Schwab Investment Management Inc. boosted its position in shares of Neumora Therapeutics by 139.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company's stock worth $9,224,000 after purchasing an additional 406,891 shares during the period. Cerity Partners LLC acquired a new stake in Neumora Therapeutics in the 3rd quarter valued at approximately $3,209,000. Point72 Asset Management L.P. purchased a new stake in Neumora Therapeutics in the third quarter valued at approximately $1,097,000. Finally, State Street Corp raised its position in Neumora Therapeutics by 65.3% in the third quarter. State Street Corp now owns 1,790,707 shares of the company's stock valued at $23,655,000 after purchasing an additional 707,409 shares during the period. 47.65% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Neumora Therapeutics Stock Down 2.6 %

Shares of NASDAQ NMRA traded down $0.03 during midday trading on Tuesday, hitting $1.13. The stock had a trading volume of 1,944,706 shares, compared to its average volume of 1,431,006. The stock has a 50 day simple moving average of $1.75 and a 200-day simple moving average of $7.99. The company has a market capitalization of $183.04 million, a PE ratio of -0.60 and a beta of 2.59. Neumora Therapeutics has a 1 year low of $1.13 and a 1 year high of $17.19.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.46) by $0.09. As a group, analysts expect that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.